Dupont Capital Management’s CERo Therapeutics Warrants CEROW Stock Holding History

Dupont Capital Management’s Portfolio CEROW Stock Details CEROW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,500	Closed	-$166	–	111
2025 Q3	$166	Hold	12,500	–	–	﹤0.01%	95
2025 Q2	$263	Hold	12,500	–	–	﹤0.01%	95
2025 Q1	$166	Hold	12,500	–	–	﹤0.01%	95
2024 Q4	$104	Hold	12,500	–	–	﹤0.01%	98
2024 Q3	$64	Hold	12,500	–	–	﹤0.01%	114
2024 Q2	$250	Hold	12,500	–	–	﹤0.01%	114
2024 Q1	$1.11K	Hold	12,500	–	–	﹤0.01%	113
2023 Q4	$344	Hold	12,500	–	–	﹤0.01%	119
2023 Q3	$895	Hold	12,500	–	–	﹤0.01%	161
2023 Q2	$819	Hold	12,500	–	–	﹤0.01%	563
2023 Q1	$625	Hold	12,500	–	–	﹤0.01%	680
2022 Q4	$491	Hold	12,500	–	–	﹤0.01%	1295
2022 Q3	$2K	Hold	12,500	–	–	﹤0.01%	1397
2022 Q2	$1K	Hold	12,500	–	–	﹤0.01%	1586
2022 Q1	$3K	Hold	12,500	–	–	﹤0.01%	1630
2021 Q4	$5K	Buy	+12,500	New	+$5.76K	﹤0.01%	1660

Other funds holding CEROW

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Dupont Capital Management's CEROW Position: Q4 2025 in Review

Dupont Capital Management sold out of CERo Therapeutics Warrants (CEROW) in Q4 2025, closing a stake of 12,500 shares — an estimated $166 sold.

Dupont Capital Management first reported a position in CEROW in Q4 2021 and held it in 16 quarters. The position peaked at $5K in Q4 2021. 1 fund tracked by Wall St. Rank holds CEROW as of Q4 2025.

Dupont Capital Management reported no remaining CERo Therapeutics Warrants position as of Q4 2025 after selling out during the quarter.
Dupont Capital Management sold 12,500 CERo Therapeutics Warrants shares in Q4 2025, an estimated $166.
Dupont Capital Management first reported a position in CERo Therapeutics Warrants in Q4 2021 and held it in 16 quarters.
Dupont Capital Management's CERo Therapeutics Warrants position peaked at $5K in Q4 2021.
1 fund tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q4 2025.

Based on Dupont Capital Management's 13F filing for Q4 2025, filed 26 Jan 2026.